. 2022 Jan 21;14(3):547. doi: 10.3390/cancers14030547

Table 1.

Molecular cues sustaining cell dormancy and specific markers of CSCs in different tumor types.

Tumor Type	Metastatic Site	Dormancy Factor	Mechanism	Ref	CSC Markers	Ref
Breast	Lung	Fbxw7	Increased levels	[34]	CD44⁺CD24⁻/^low ALDH⁺	[192,193]
	Lung	ATG7	Increased levels	[63]
	Lung	CXCR4	Decreased levels	[194]
	Lung	OXPHOS	Activation	[142,164,173]
		ARHI	Increased levels	[58]
		IFN-β/IFNAR/IRF7	Activation	[80]
		NRF2	Activation	[150]
	Bone marrow	LIFR	Increased levels	[108]
	Bone	MSK1	Increased levels	[195]
	Multiple sites	IKKβ	Activation	[76]
	Intraperitoneal	KiSS1	Increased levels	[35]
	Lung	NR2F1/DEC2/p27	Increased levels	[100]
		AMPK/OXPHOS	Activation	[147]
HNSCC	Lymph nodes	PRRX1	Increased levels	[196]	CD44⁺ ALDH⁺ BMI-1	[197,198,199]
	Bone marrow	NR2F1/NANOG	Increased levels	[41,99]
	Bone marrow	TGFβ2	Increased levels	[200]
Melanoma	Lung	KiSS1	Increased levels	[37]	ABCB5⁺ CD20⁺ CD271⁺	[201,202,203]
Melanoma		OXPHOS	Activation	[143,144]	ABCB5⁺ CD20⁺ CD271⁺	[201,202,203]
Ovarian		KiSS1	Increased levels	[36]	CD44⁺, CD117⁺ CD133⁺ SP	[204,205,206]
	Intraperitoneal sites	MKK4	Increased levels	[207]
		ARHI	Increased levels	[56,57]
Prostate		Lipid metabolism	Activation	[156]	Sca1⁺, CD133⁺ CD44⁺ A₂β₁ ^hi	[208,209]
	Bone marrow	TBK1	Increased levels	[72]
	Bone	BMP-7	Increased levels	[210]
	Bone	Wnt5a	Increased levels	[211]
	Liver, Lymph node, Bone	GAS6/AXL	Increased levels	[212]
	Bone	GDF10/TGFβ2/TGF-βRIII	Increased levels	[213]
	Bone marrow	NR2F1/NANOG	Increased levels	[41]
Pancreas	Liver and Lung	KRAS/C-Myc, IGF1/AKT	Activation	[51]	CD44⁺, CD24^+, ESA⁺, CD133⁺	[214,215,216]
Pancreas		OXPHOS	Activation	[157,165]	CD44⁺, CD24^+, ESA⁺, CD133⁺	[214,215,216]